Three-dimensional quantitative structurefarnesyltransferase inhibition analysis for some diaminobenzophenones

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 6, 2009, Pages 1220-1228

  Xie, Aihua ^a   Clark, Shawna R ^a,b   Prasanna, Sivaprakasam ^a   Doerksen, Robert J ^a,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b TOUGALOO COLLEGE   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Benzophenone; CoMFA; CoMSIA; Farnesyltransferase; Malaria

Indexed keywords

2 (AMINOACYLAMINO)BENZOPHENONE; 5 ARYLACRYLAMINOBENZOPHENONE; BENZOPHENONE DERIVATIVE; CINNAMIC ACID DERIVATIVE; DIAMINOBENZOPHENONE; FURAN DERIVATIVE; N ( 4 ACYLAMINO 3 BENZOYLPHENYL) 3 [ 5 ( 4 NITROPHENYL) 2 FURYL]ACRYLIC ACID AMIDE; N ( 4 ACYLAMINO 3 BENZOYLPHENYL) 4 NITROCINNAMIC ACID AMIDE; N ( 4 AMINOACYLAMINO BENZOYLPHENYL) 3 [ 5 ( 4 NITROPHENYL) 2 FURYL]ACRYLIC ACID AMIDE; N ( 4 TOLYLACETYLAMINO 3 BENZOYLPHENYL) 3 ARYLFURYLACRYLIC ACID AMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; DIAMINE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE;

ANIMAL CELL; ANTIMALARIAL ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; ELECTRICITY; ENZYME ACTIVITY; HYDROPHOBICITY; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; THREE DIMENSIONAL IMAGING; YEAST; CHEMICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; STATIC ELECTRICITY;

ANTIMALARIALS; BENZOPHENONES; DIAMINES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HYDROPHOBICITY; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STATIC ELECTRICITY;

EID: 73949132076     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360902781389     Document Type: Article

References (37)

1. Bell DR, Jorgensen P, Christophel EM, Palmer KL. Malaria risk estimation of the malaria burden. Nature 2005;437:E3-4.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of plasmodium falciparum malaria. Nature 2005;434:214-217
3. Rosenthal PJ. Antimalarial drug discovery: old and new approaches. J Exp Biol 2003;206:3735-3744
4. Schlitzer M. Malaria chemotherapeutics part 1: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem 2007;2:944-986
5. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005;352:1565-1577
6. Brady RL, Cameron A. Structure-based approaches to the development of novel anti-malarials. Curr Drug Target 2004;5:137-149
7. Eastman RT, White J, Hucke O, Bauer K, Yokoyama K, Nallan L, Chakrabarti D, Verlinde CLMJ, Gelb MH, Rathod PK, Van Voorhis WC. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem 2005;280:13554-13559
8. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004;3:509-520
9. Wiesner J, Ortmann R, Jomaa H, Schlitzer M. New antimalarial drugs. Angew Chem Int Ed Engl 2003;42:5274-5293
10. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 2006;47:233-240
11. Gelb MH, Van Voorhis WC, Buckner FS, Yokoyama K, Eastman R, Carpenter EP, Panethymitaki C, Brown KA, Smith DF. Protein farnesyl and n-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 2003;126:155-163
12. Appels NMGM, Beijnen JH, Schellens JHM. Development of farnesyl transferase inhibitors: a review. Oncologist 2005;10:565-578
13. Dinsmore CJ, Bell IM. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity. Curr Top Med Chem 2003;3:1075-1093
14. Pan J, Yeung S-CJ. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005;65:9109-9112
15. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyl transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:6584-6593
16. Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem 2004;12:6517-6526
17. Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Horney CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, Chakrabarti D, Gelb MH, VanVoorhis WC. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem 2005;48:3704-3713
18. Wiesner J, Kettler K, Sakowski J, Ortmann R, Katzin AM, Kimura EA, Silber K, Klebe G, Jomaa H, Schlitzer M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew Chem Int Ed Engl 2004;43:251-254
19. Kettler K, Sakowski J, Silber K, Sattler I, Klebe G, Schlitzer M. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)- 3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem 2003;11:1521-1530
20. Kettler K, Wiesner J, Fucik K, Sakowski J, Ortmann R, Dahse H-M, Jomaa H, Schlitzer M. 2-(Aminoacylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity. Pharmazie 2005;60:677-682
21. Kettler K, Wiesner J, Silber K, Haebel P, Ortmann R, Sattler I, Dahse H-M, Jomaa H, Klebe G, Schlitzer M. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl] acrylic acid amides and their antimalarial activity. Eur J Med Chem 2005;40:93-101.
22. Mitsch A, Bohm M, Wißner P, Sattler I, Schlitzer M. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. Bioorg Med Chem 2002;10:2657-2662
23. Mitsch A, Wißner P, Silber K, Haebel P, Sattler I, Klebe G, Schlitzer M. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3- benzoylphenyl)-3-arylfurylacrylic acid amides. Bioorg Med Chem 2004;12:4585-4600
24. Sakowski J, Sattler I, Schlitzer M. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides. Bioorg Med Chem 2002;10:233-239 (Pubitemid 33121249)
25. Cramer RD III, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959-5967
26. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-4146
27. Equbal T, Silakari O, Ravikumar M. Exploring three-dimensional quantitative structural activity relationship (3D-QSAR) analysis of SCH 66336 (Sarasar) analogues of farnesyltransferase inhibitors. Eur J Med Chem 2008;43:204-209
28. Murumkar PR, Giridhar R, Yadav MR. 3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. Chem Biol Drug Des 2008;71:363-373
29. Puntambekar DS, Giridhar R, Yadav MR. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. Eur J Med Chem 2006;41:1279-1292
30. Puntambekar DS, Giridhar R, Yadav MR. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. Eur J Med Chem 2008;43:142-154
31. Sung ND, Cho YK, Kwon BM, Hyun KH, Kim CK. 3D QSAR studies on cinnamaldehyde analogues as farnesyl protein transferase inhibitors. Arch Pharm Res 2004;27:1001-1008
32. Xie A, Sivaprakasam P, Doerksen RJ. 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold. Bioorg Med Chem 2006;14:7311-7323
33. Sybyl 7.2. St. Louis, MO: Tripos, Inc., 2005.
34. Grubbs F. Procedures for detecting outlying observations in samples. Technometrics 1969;11:1-21.
35. Fucik K, Kettler K, Wiesner J, Ortmann R, Unterreitmeier D, Krauss J, Bracher F, Jomaa H, Schlitzer M. 2-(Arylpropionylamino)- and 2-(arylacryloylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity. Pharmazie 2004;59:744-752
36. Wiesner J, Ortmann R, Mitsch A, Wißner P, Sattler I, Jomaa H, Schlitzer M. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity. Pharmazie 2003;58:288-289
37. Bohm M, Mitsch A, Wißner P, Sattler I, Schlitzer M. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors. J Med Chem 2001;44:3117-3124